13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001482416
Total reported value
$604.3M
$604.3M
50 檔
24.6%
At the close of Q1 2024, Sio Capital Management, LLC disclosed equity holdings valued at approximately $604.3M, spread across 50 reported holdings.
During Q1 2024, Sio Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Laboratory Corp. of America | Stock-Other | 14.69% | — | +36.81% | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 11.01% | — | +58.14% | |
| 3 | CI | THE Cigna Group | Stock-Healthcare | 8.23% | +2.63% | NEW | |
| 4 | GMED | Globus Medical Inc - A | Stock-Healthcare | 6.28% | +3.95% | NEW | |
| 5 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 4.06% | — | — | |
| 6 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 3.36% | +0.74% | -53.89% | |
| 7 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 2.92% | +1.06% | +2.60% | |
| 8 | IRWD | Ironwood Pharmaceuticals Inc | Stock-Other | 2.91% | — | +585.56% | |
| 9 | MDT | Medtronic plc | Stock-Healthcare | 2.72% | +1.84% | NEW | |
| 10 | OGN | Organon & Co | Stock-Healthcare | 2.68% | -0.74% | EXIT | |
| 11 | TYRA | Tyra Biosciences Inc | Stock-Other | 2.62% | +0.35% | — | |
| 12 | EMBC | Embecta CORP | Stock-Healthcare | 2.31% | -2.34% | EXIT | |
| 13 | TFX | Teleflex Inc | Stock-Healthcare | 2.28% | -1.63% | EXIT | |
| 14 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.88% | — | — | |
| 15 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.87% | — | +54.21% | |
| 16 | HUMA | Humacyte Inc | Stock-Other | 1.85% | — | — | |
| 17 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.80% | -1.60% | — | |
| 18 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.72% | — | — | |
| 19 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.63% | — | -51.52% | |
| 20 | HCSG | Healthcare Services Group | Stock-Other | 1.57% | — | -48.01% | |
| 21 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.54% | — | — | |
| 22 | ✓ | Fusion Pharmaceuticals Inc | Stock-Other | 1.54% | — | -1.22% | |
| 23 | ERAS | Erasca Inc | Stock-Other | 1.49% | -0.01% | EXIT | |
| 24 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 1.49% | — | — | |
| 25 | NUVB | Nuvation Bio Inc | Stock-Other | 1.45% | — | — | |
| 26 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.45% | — | — | |
| 27 | IART | Integra Lifesciences Holding | Stock-Other | 1.45% | -0.52% | EXIT | |
| 28 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.04% | -0.30% | -60.57% | |
| 29 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.04% | — | — | |
| 30 | PCRX | Pacira Biosciences Inc | Stock-Other | 0.97% | — | — | |
| 31 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 0.92% | -0.07% | EXIT | |
| 32 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.91% | — | — | |
| 33 | ✓ | Modular Med Inc | Stock-Other | 0.85% | — | +123.30% | |
| 34 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.84% | — | — | |
| 35 | RVNCEUR | Revance Therapeutics Inc | Stock-Other | 0.69% | — | — | |
| 36 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.62% | — | — | |
| 37 | BOLD | Boundless Bio Inc | Stock-Other | 0.61% | -0.03% | EXIT | |
| 38 | APRE | Aprea Therapeutics Inc | Stock-Other | 0.55% | — | -1.21% | |
| 39 | ✓ | Third Harmonic Bio Inc | Stock-Other | 0.46% | — | — | |
| 40 | PRLD | Prelude Therapeutics Inc | Stock-Other | 0.45% | — | — | |
| 41 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.43% | +2.96% | NEW | |
| 42 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.24% | -0.08% | EXIT | |
| 43 | ✓ | Nyxoah S A | Stock-Other | 0.20% | -0.02% | EXIT | |
| 44 | ✓ | Vincerx Pharma Inc | Stock-Other | 0.15% | — | — | |
| 45 | NXTCEUR | Nextcure Inc | Stock-Other | 0.09% | — | — | |
| 46 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.07% | — | — | |
| 47 | ✓ | Aslan Pharmaceuticals LTD | Stock-Other | 0.05% | — | — | |
| 48 | RCKTW | Rocket Pharmaceuticals In-27 | Stock-Other | 0.03% | — | — | |
| 49 | HUMAW | Humacyte Inc-cw27 | Stock-Other | 0.01% | — | — | |
| 50 | ✓ | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Sio Capital Management, LLC reported a total U.S. public equity portfolio value of $604.3M across 50 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including Laboratory Corp. of America, INSM, CI) accounted for 24.6% of total reported equity market value during Q1 2024.
During Q1 2024, Sio Capital Management, LLC's top holdings by market value included Laboratory Corp. of America (14.7%)、INSM (11.0%)、CI (8.2%). The largest single position, Laboratory Corp. of America, represented 14.7% of total portfolio value.
In Q1 2024, Sio Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.